CRN04777 Given Rare Pediatric Disease Designation for Congenital Hyperinsulinism
In a recent press release, clinical-stage pharmaceutical company Crinetics Pharmaceuticals announced that their investigational drug candidate, CRN04777, received Rare Pediatric Disease designation from the FDA. The therapy is designed…